- Home
- BIIB vs FDS Comparison
BIIB vs FDS Comparison
Compare BIIB & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FDS
- Stock Information
- Founded
- BIIB 1978
- FDS 1978
- Country
- BIIB United States
- FDS United States
- Employees
- BIIB N/A
- FDS N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FDS Computer Software: Programming Data Processing
- Sector
- BIIB Health Care
- FDS Technology
- Exchange
- BIIB Nasdaq
- FDS Nasdaq
- Market Cap
- BIIB 22.2B
- FDS 18.0B
- IPO Year
- BIIB 1991
- FDS 1996
- Fundamental
- Price
- BIIB $143.06
- FDS $454.42
- Analyst Decision
- BIIB Buy
- FDS Sell
- Analyst Count
- BIIB 26
- FDS 13
- Target Price
- BIIB $234.79
- FDS $459.75
- AVG Volume (30 Days)
- BIIB 1.4M
- FDS 314.6K
- Earning Date
- BIIB 02-11-2025
- FDS 12-19-2024
- Dividend Yield
- BIIB N/A
- FDS 0.92%
- EPS Growth
- BIIB 10.05
- FDS 12.98
- EPS
- BIIB 11.06
- FDS 13.96
- Revenue
- BIIB $9,607,500,000.00
- FDS $2,229,507,000.00
- Revenue This Year
- BIIB N/A
- FDS $5.63
- Revenue Next Year
- BIIB N/A
- FDS $5.72
- P/E Ratio
- BIIB $13.58
- FDS $32.59
- Revenue Growth
- BIIB N/A
- FDS 5.02
- 52 Week Low
- BIIB $142.42
- FDS $391.84
- 52 Week High
- BIIB $252.17
- FDS $499.87
- Technical
- Relative Strength Index (RSI)
- BIIB 31.71
- FDS 31.46
- Support Level
- BIIB $149.73
- FDS $446.99
- Resistance Level
- BIIB $150.48
- FDS $487.40
- Average True Range (ATR)
- BIIB 3.56
- FDS 7.77
- MACD
- BIIB 0.18
- FDS -3.58
- Stochastic Oscillator
- BIIB 4.59
- FDS 16.15
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the Global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for 82% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.